Bioengineering news story
Researchers have uncovered critical insights into the immune dynamics of people living with HIV (PLWH) who transition from traditional daily oral therapies to the long-acting injectable regimen consisting of cabotegravir and rilpivirine.
Investigators published a comprehensive study in Scientific Reports, detailing the dynamic changes occurring in the immune profiles of PLWH undergoing this treatment switch. Their work elucidates how monocyte subsets, key players in innate immunity and inflammatory processes, adapt over time to injections of cabotegravir plus rilpivirine. Understanding these immunological recalibrations is indispensable, as chronic immune activation and inflammation in HIV are tightly linked to non-AIDS comorbidities and overall disease progression.
Read the full news story here.
Source : Bioengineering
Related HIV and Co-Infections News
-
[BHIVA/BASHH 2026] HIV i-Base: HIV and neurodiversity includes higher concerns over adherence
-
Queen Mary University of London: Scientists discover how HIV hijacks a cellular ‘gateway’ to infect resting immune cells
-
Science: A novel gene-therapy approach to ‘functionally cure’ HIV succeeds in some monkeys
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.